Phyton Biotech Files Patent Infringement Lawsuit against Samyang

Phyton Biotech GmbH, an affiliate of Phyton, Ltd., announced today that it has filed a patent infringement lawsuit in the Federal Republic of Germany against Samyang Corporation, including its subsidiary Samyang Genex Corporation. The core issue of the lawsuit is Samyang´s use of enhanced plant cell fermentation technology using cell lines derived from Taxus species to produce paclitaxel. Phyton developed, patented, and commercialized plant cell fermentation technology, and believes Samyang´s paclitaxel production system is infringing on Phyton´s patented technology.

Among other things, the complaint requests the German court to order Samyang to cease and desist from offering, putting on the market, selling, owning, or otherwise using paclitaxel active pharmaceutical ingredient (API) in the Federal Republic of Germany.

Harald Heckenmueller, General Manager, stated, "Phyton has created much innovation and a number of patents around plant cell fermentation and taxanes such as paclitaxel and docetaxel. We intend to vigorously defend our rights under these patents."

About Phyton

Phyton Ltd. is headquartered in San Antonio, Texas, USA, and through its affiliates Phyton Biotech GmbH and Phyton Biotech LLC (collectively known as "Phyton Biotech"), is a global supplier of high quality paclitaxel and docetaxel API. With development and manufacturing facilities near Hamburg, Germany and Vancouver, Canada, the company also has R&D capabilities via plant cell fermentation (PCF TM) and chemical synthesis to develop APIs derived from secondary plant metabolites, recombinant proteins, or other starting materials for its customers.